The Curafutura association said that around a fifth of all medicine costs – some CHF8 million ($8.5 billion) per year – are accounted for by just 20 drugs. Of these, seven are based on an opaque pricing model, where “only the public or showcase price is known”, the association said at an annual press conference.
According to a new analysis presented by the group, the 20 medicines generated profits of CHF1.7 billion between October 2021 and September 2022 – a margin increase of 13%, compared to 5% for other medicines on the federal list of specialist drugs.
The seven drugs described as lacking transparency were related to the treatment of various types of cancer, multiple sclerosis, psoriasis, and cystic fibrosis.
More
More
The end of affordable medicine
This content was published on
Pharma companies are close to a cure for cancer, but will the hefty price tags make treatments unaffordable for most of the world?
Curafutura said the government’s plans to further expand the use of a confidential pricing model was questionable, as evidence shows that it has not led to lower prices. In fact, the highest spending was for the seven drugs that lacked transparent prices. As a result, the association suggests other models to stabilise prices should be considered.
This is also backed up by a study from the University of Zurich published last year that found using confidential discounts on cancer and other drugs does little to make them available faster and at more affordable prices.
The rising cost of healthcare, and how to best control it, is a perennial concern both for the Swiss government and population. In 2023, the cost of compulsory health insurance is to increase by an average of 6.6%, the biggest annual rise in a decade. The price of an average monthly adult premium is set to climb to almost CHF400.
More
More
Health insurance premiums to take biggest jump in a decade
This content was published on
The cost of compulsory health insurance in Switzerland is to increase by an average of 6.6% in 2023.
Should Switzerland take measures to support its struggling industries?
Industrial policies are back in fashion, not only in the United States but also in the EU. Should Switzerland, where various industries are struggling, draw inspiration from such policies?
As a Swiss Abroad, how do you feel about the emergence of more conservative family policies in some US states?
In recent years several US states have adopted more conservative policies on family issues, abortion and education. As a Swiss citizen living there, how do you view this development?
This content was published on
The parents of the young jihadist who left for Syria to join the Islamic State have been given suspended sentences by the Federal Criminal Court.
This content was published on
Felix Lehner, Pamela Rosenkranz and Miroslav Sik have been awarded the Swiss Grand Award for Art/Prix Meret Oppenheim 2025.
Nearly 2% of new Swiss disability insurance claims involve Long Covid
This content was published on
Just under 2% of new claims submitted to the disability insurance between 2021 and 2023 concern people suffering from Long Covid.
This content was published on
The watch industry had to contend with a weakening of its exports last year, which reached a volume of CHF25.9 billion ($28.5 billion).
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Secret discounts leave patients at drugmakers’ mercy
This content was published on
A University of Zurich study has found that using confidential discounts on drugs does little to make them available faster and more affordable.
This content was published on
Healthcare costs, the pension system and climate change are the top three burning issues for the Swiss, according to a survey.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.